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ABSTRACT
Collagen cross‐linking is altered in many diseases of bone, and enzymatic collagen cross‐links are important to bone quality, as
evidenced by losses of strength after lysyl oxidase inhibition (lathyrism). We hypothesized that cross‐links also contribute directly to
bone fracture toughness. A mouse model of lathyrism using subcutaneous injection of up to 500mg/kg b‐aminopropionitrile (BAPN)
was developed and characterized (60 animals across 4 dosage groups). Three weeks of 150 or 350mg/kg BAPN treatment in young,
growing mice signiﬁcantly reduced cortical bone fracture toughness, strength, and pyridinoline cross‐link content. Ratios reﬂecting
relative cross‐link maturity were positive regressors of fracture toughness (HP/[DHLNLþHLNL] r2¼ 0.208, p< 0.05; [HPþ LP]/
[DHNLþHLNL] r2¼ 0.196, p< 0.1), whereas quantities of mature pyridinoline cross‐links were signiﬁcant positive regressors of tissue
strength (lysyl pyridinoline r2¼ 0.159, p¼ 0.014; hydroxylysyl pyridinoline r2¼ 0.112, p< 0.05). Immature and pyrrole cross‐links,
which were not signiﬁcantly reduced by BAPN, did not correlate with mechanical properties. The effect of BAPN treatment on
mechanical properties was dose speciﬁc, with the greatest impact found at the intermediate (350mg/kg) dose. Calcein labeling was
used to deﬁne locations of new bone formation, allowing for the identiﬁcation of regions of normally cross‐linked (preexisting) and
BAPN‐treated (newly formed, cross‐link‐deﬁcient) bone. Raman spectroscopy revealed spatial differences attributable to relative
tissue age and effects of cross‐link inhibition. Newly deposited tissues had lower mineral/matrix, carbonate/phosphate, and Amide I
cross‐link (matrixmaturity) ratios comparedwith preexisting tissues. BAPN treatment did not affectmineral measures but signiﬁcantly
increased the cross‐link (matrix maturity) ratio compared with newly formed control tissue. Our study reveals that spatially localized
effects of short‐term BAPN cross‐link inhibition can alter the whole‐bone collagen cross‐link proﬁle to a measureable degree, and this
cross‐link proﬁle correlates with bone fracture toughness and strength. Thus, cross‐link proﬁle perturbations associated with bone
disease may provide insight into bone mechanical quality and fracture risk. © 2014 American Society for Bone and Mineral Research.
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Introduction
Resistance to fracture is dependent not only on the quantityand distribution of bone but also on the quality of the bone
material.(1–3) As a hierarchical composite primarily composed of
mineral and Type I collagen matrix, the strength and toughness
of bone tissue are derived from its components’ individual
properties, as well as their interfaces and arrangements at
multiple length scales. A stiff bone is desirable as a skeletal
support, but tough bone is necessary to resist fracture.(4–6)
Toughness is supplied primarily by the organic matrix,(3,7,8) and
the task of stabilizing this polymeric network rests on a collection
of covalent collagen cross‐links.(9–12)
Numerous species of collagen cross‐links have been character-
ized.(13–17) The conversion of collagen telopeptide lysines to
allysines by the extracellular enzyme lysyl oxidase (LOX) is required
for the formation of enzymatically controlled cross‐links during
tissue development.(18) LOX‐produced allysines react with helix
(hydroxy)lysines on neighboring collagen molecules to form
immature divalent cross‐links, quantiﬁed as their reduced forms
dihydroxylysinorleucine (DHLNL) and hydroxylysinorleucine
(HLNL). A fraction of these cross‐links will subsequently mature
to trivalent forms, known to include both the pyridinolines
(hydroxylysylpyridinoline [HP] and lysylpyridinoline [LP]) and
pyrroles. Advanced glycation endproduct (AGE) cross‐links, such
as pentosidine (PEN), form independently of enzyme activity in the
presence of sugars with net accumulation determined by their rate
of formation and removal via tissue turnover. Shifts in cross‐link
proﬁle occur in many bone pathologies and with aging,(19–22) and
understanding which of these changes are signiﬁcant to bone
fracture resistance is critical for developing and evaluating
therapies for fracture prevention and disease management.
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There are many reports of enzymatic and AGE cross‐links
differing in their contribution to bone mechanics,(1,19,21,23,24) but
a full characterization of cross‐link proﬁle (eg, immature versus
mature, hydroxylation level, enzymatic versus AGE) with direct
correlations to tissue fracture toughness is unknown. Inhibition
of lysyl oxidase by treatment with b‐aminopropionitrile (BAPN),
known as lathyrism, inhibits enzymatic cross‐link formation in
forming collagen and reduces bone strength in vivo.(25–27) The
majority of studies investigating the effects of BAPN on bone use
animal models no smaller than rats.(27–30) Most commonly, BAPN
is administered through diet or ingested ﬂuids, which make the
dose difﬁcult to control.(25,27,30,31) Subcutaneous BAPN injection
of mice was chosen in this study to allow for dosage control of
cross‐link inhibition in an inexpensive animal model. Enzymatic
cross‐linking occurs primarily during tissue formation. Thus,
young, growing mice were chosen so that signiﬁcant quantities
of cross‐link–deﬁcient tissuewere deposited during the course of
BAPN exposure. Cross‐link proﬁle (DHLNL, HLNL, HP, LP, Pyrrole,
and PEN), whole‐bone mechanical properties, fracture tough-
ness, and localized matrix composition were measured on hind
limb bones from mice treated with 0 to 500mg BAPN/kg body
weight from 5 to 8 weeks of age. We hypothesized that shifts in
cross‐link proﬁle after BAPN treatment would be dose depen-
dent and would speciﬁcally correlate with resulting reductions in
bone fracture toughness and strength.
Materials and Methods
Animals and BAPN treatment
All animal procedures were performed at the University of
Michigan with University Committee on Use and Care of Animals
(UCUCA) approval. Sixty male C57Bl6 mice (Charles River
Laboratories, Wilmington, MA, USA) were weight‐matched into
4 experimental groups 2 days before the start of the experiment.
Animals were group housed in standard cages with free access to
standard chow, water, and cage activity. All mice underwent
3 weeks of treatment beginning when mice reached 5 weeks of
age. Treatment consisted of daily subcutaneous injections of
phosphate buffered saline (PBS) containing 0, 150, 350, or 500mg/
kg BAPN (b‐aminopropionitrile fumarate, Sigma‐Aldrich, St. Louis,
MO, USA). Mice were weighed and dosages adjusted every 3 days
during the course of the 21‐day experiment. On experiment days 2
and 16, mice received 15mg/kg calcein (Sigma) by intraperitoneal
injection. Mice were euthanized by CO2 inhalation on day 22 at
8 weeks of age. Femora and tibias were immediately harvested,
cleaned of soft tissue, wrapped in calcium‐buffered PBS (Ca‐PBS)–
soaked gauze and frozen until use.
mCT
Whole left tibias and femora (n¼ 15/group) were scanned while
submerged in Ca‐PBS using an eXplore Locus SP scanner (GE
Healthcare Pre‐Clinical Imaging, London, Canada) at a voxel
size of 18mm3 (80 kVp, 80mA, 1600ms, 0.508mm Al ﬁlter).(32)
Calibration of the scanner using an air/water/hydroxyapatite
(HA) phantom was performed each day of scanning. Regions of
interest were analyzed using a combination of GE MicroView
software (reorientation, standard site selection, tissue mineral
content [TMC] and tissue mineral density [TMD]) and custom‐
written MATLAB scripts (quantiﬁcation of cortical geometry).
Scans were reoriented to match the alignment of each bone
in silico with its eventual alignment during mechanical testing. A
ﬁve‐slice‐thick standard site was taken from each reoriented tibia
at the point 23.5% of the distance from the tibia‐ﬁbula junction
to the proximal end of the tibia, closely corresponding to the
center of the 3mm mechanical testing span for all bones. Thus,
the cortical site analyzed was reproducible from bone to bone
and appropriate for calculating tissue level properties from four‐
point testing data using classic beam theory. For the femur, a
ﬁve‐slice standard site was located at the site 48% of its length as
measured from the distal condyle. TMC and TMDweremeasured
for both the femur and tibia using a ﬁxed threshold of 2000
Hounsﬁeld Units.
Four‐point bending
AftermCT scanning, left tibias (n¼ 15/group) were tested in four‐
point bending on an eXpert 450 Universal Testing Machine
(Admet, Norwood, MA, USA) as previously described.(33) Brieﬂy,
bones were oriented with the medial surface in tension and
loaded at a displacement rate of 0.025mm/s. Bones were
hydrated with Ca‐PBS at all times. Load and displacement
(structural‐level) data were recorded and tissue stress and strain
were estimated from the structural‐level data using beam theory
and the tibia standard site cross‐sectional geometry measured
by mCT. Whole‐bone (load, displacement) and estimated tissue
level (stress, strain) properties were quantiﬁed at the yield and
ultimate points. Yield was deﬁned using the 0.2% strain offset
method. Whole‐bone stiffness and estimated tissue elastic
modulus were calculated by linear regression ﬁtting of the
linear‐elastic pre‐yield region. Pre‐yield work and estimated pre‐
yield toughness (resilience) were calculated as the area under the
load‐displacement and stress‐strain curves, respectively, up to
the previously deﬁned yield point.
Notched toughness testing
A notched toughness test was performed on the right femora.(34)
A sharp notch was cut through the anterior surface of the mid‐
diaphysis using a razor blade lubricated with 1mm diamond
suspension (MetaDi Supreme, Buehler, Lake Bluff, IL, USA) and a
custom‐built jig. Razor cutting depth was controlled using a
micrometer. Notched boneswere tested to catastrophic failure in
three‐point bending at 0.001mm/s. Load and deﬂection were
recorded during each test. After fracture, bones were brieﬂy
soaked in diluted household bleach to remove marrow from the
fracture surface and then dehydrated in a graded ethanol series.
Fracture surfaces were imaged under back‐scattering scanning
electronmicroscopy (SEM, Hitachi S3200N, Hitachi, Tokyo, Japan)
and analyzed using a custom MATLAB script to quantify bone
geometry, half‐notch and half‐crack angles, and calculate
maximum load (KC.Max) and instability (KC.Inst) toughness.
(34) KC.
Max was calculated using the ultimate force and half‐notch angle.
KC.Inst was calculated using the force at catastrophic fracture and
instability half‐crack angle. Notch and crack geometry met the
assumptions of the thick‐walled cylinder crack propagation
model, with half‐notch/crack angles less than 110°.(34) Sample
sizes were 7 to 10 per group.
Collagen cross‐link quantification
Left femora were used for collagen cross‐link quantiﬁcation (n¼ 7
to 11/group). Mature (HP, LP, and pyrrole), reduced immature
(DHLNL and HLNL), and glycation (PEN) cross‐links were all
measured from the same sample and normalized to collagen
content. Cortical diaphyses, ﬂushed of marrow, were demineral-
ized in 0.5M EDTA. After extensive washing, demineralized
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samples were reacted with sodium borohydride to stabilize
immature cross‐links in preparation for acid hydrolysis.(35) Because
pyrrole cross‐links are neither reducible nor stable in strong acid,
reduced sampleswere ﬁrst digestedwith TPCK‐treated trypsin in a
shaking water bath at 37°C for 22 hours.(35) An aliquot of digest
was used to quantify pyrrole content colorimetrically in a 384‐well
plate.(35) The remaining digest was mixed 1:1 with 12M HCl and
hydrolyzed at 110°C for 12 hours. An aliquot of the resulting
hydrolysate was used for hydroxyproline quantiﬁcation to
determine collagen content.(36) Another aliquot was mixed with
an internal standard (Quidel, San Diego, CA, USA) and applied to
an SPE column (Chromabond X‐Links, Machery‐Nagel, Germany)
optimized for the puriﬁcation of collagen cross‐links from
biological samples.(37) Cross‐links and internal standard were
eluted from the SPE column in 600mL of 1% heptaﬂuorobutyric
acid (HFBA) in preparation for HPLC injection.
HP and LP were quantiﬁed using a commercially available
standard (Quidel). Pentosidine was synthesized as polypentosi-
dine, hydrolyzed, and puriﬁed as described.(38) Further puriﬁca-
tion on Chromabond Cross‐links SPE columns and by HPLC peak
fraction collection yielded a pentosidine standard that matched
published absorption and ﬂuorescence proﬁles.(39) The pento-
sidine standard was calibrated from its absorbance at 326 nm in
1mM HCl.(40) Standards for DHLNL and HLNL were a generous
gift from Simon Robins (University of Aberdeen).
All cross‐links but the pyrroles were quantiﬁed using a binary
pumpWaters BreezeHPLC system (Waters Corp., Milford, MA, USA)
ﬁtted with a column heater (set to 30°C) and Waters 2475
ﬂuorescence detector. Samples were separated on a Waters
XBridge C18 column (3.5mm, 4.6 150mm). Buffer A consisted of
0.12% HFBA and buffer B consisted of 50% acetonitrile. The
naturally ﬂuorescent cross‐links were quantiﬁed in a single
injection by monitoring at 297nm/395nm (HP, LP) and 335nm/
385nm (PEN) ex/em wavelengths (10 minutes 85% A, linear
gradient 85% to 75% A over 30 minutes, 10 minutes 75% A). The
reduced immature cross‐linkswere quantiﬁed in a second injection
with the addition of an o‐phthalaldehyde (OPA) post‐column
reaction (isocratic, 85% A). OPA reagent (0.8 g OPA dissolved in
15mL ethanol, added to 980mL boric acid buffer [0.4M, pH 10],
2mLmercaptoethanol, and 1g Brij‐35) was delivered using a high‐
pressure syringe pump (Nexus 5000, Chemyx, Stafford, TX, USA) at
a rate of 0.5mL/min with ﬂuorescence monitored at 350nm/
450nm (ex/em).
Bone sectioning and Raman spectroscopy
Right tibias (n¼ 5 to 7/group) were dehydrated in a graded
ethanol series, cleared with Clear‐Rite 3 (Thermo Fisher Scientiﬁc,
Pittsburgh, PA, USA), and inﬁltrated and embedded using
Koldmount (SPI Supplies, West Chester, PA, USA). Sections
150mm thick were cut from the mid‐diaphysis using a low‐
speed sectioning saw (Model 650; South Bay Technology, San
Clemente, CA, USA). Sections were mounted on glass slides and
hand ground and polished to a ﬁnal thickness of 75 to 100mm.
Calcein labels were imaged on a Nikon E800 ﬂuorescence
light microscope equipped with an FITC ﬁlter and Photometrics
Coolsnap monochrome camera (Photometrics, Tucson, AZ, USA).
Using a locally constructed Raman microscope as described in
detail previously,(41) four spectra were collected from each
anatomical direction by means of line‐focused laser radiation
(785 nm excitation). Calcein images were referenced to identify
each Raman collection site as preexisting or new tissue, thus
identifying tissue age (before or with treatment) (Supplemental
Fig. S1). For all Raman spectra, both bone mineral and matrix‐
speciﬁc Raman bands were analyzed, and band intensities for
calculating the ratios of carbonate/phosphate (1070 cm1/960
cm1) and mineral/matrix (phosphate/phenylalanine, 958 cm1/
1001 cm1) were measured (GRAMS/AI software, Thermo
Nicolet, Middleton, WI, USA). The intensities of the two major
components of amide I band, identiﬁed as 1660 and 1683 cm1,
were used to calculate the cross‐link (matrix maturity) ratio. Data
were averaged for each bone section or cell culture sample
before calculating group means, thus group sample sizes reﬂect
only independent biological replicates.
Cell culture
Because bone samples included tissue varying in treatment
history and age, we used extracellular matrix produced byMC3T3‐
E1 cells to verify the effect of collagen cross‐link deﬁciency on
Raman signal. MC3T3‐E1 cells were plated in osteogenic media at
a density of 8400 cells/cm2 in six‐well plates. Media consisted ofa‐
MEM supplemented with 10% fetal bovine serum, 1% pen‐strep,
50mg/L ascorbic acid, 108M dexamethasone, 10mM b‐
glycerophosphate, and, for BAPN‐treated wells only, 1.6mM
BAPN.(42) After 2.5 weeks of culture, cell layers were scraped and
immediately transferred to a sapphire disc in aminimal amount of
media for Ramanmeasurement. Spectra were collected fromeach
samplewith the laser focusedwithin the globule ofmatrix. Raman
parameters were the same as described for tissue sections.
Statistics
All statistical analysis was performed in IBM SPSS Statistics software
(SPSS, Inc., Chicago, IL, USA). Results were checked for assumptions
of normality (Shapiro‐Wilk) and homogeneity of variance (Levene),
and, when both assumptions were valid, ANOVA tests with
Dunnett post hoc comparisons were used to check for signiﬁcant
effects of BAPN dose and speciﬁc differences between BAPN‐
treated groups and controls (0mg/kg dose). These results are
reported as the group mean the standard error of the mean. In
cases where normality tests failed, the nonparametric Jonckheere‐
Terpstra (J‐T) test for ordered alternatives was used to test for a
dose effect of BAPN. For these cases, stepwise post hoc
comparisons were used to test for speciﬁc group differences.
Results for non‐normally distributed measures are reported as
groupmedian and95%conﬁdence interval. For Ramandata, a two‐
way repeated measures ANOVA was used to test for the effects of
tissue age (within‐subject repeated measure) and BAPN dose
(between‐subjects measure). A one‐way ANOVA was also used to
test the effect of BAPN dose within new tissue only. Stepwise
multivariable linear regressions were performed with fracture
toughness and estimated material mechanical properties as
dependent variables and cross‐link measures and TMD as
independent variables. Measures of pre‐yield toughness, pento-
sidine, and pyrrole were transformed as detailed in Table 2 before
regression to meet normality assumptions. Only single‐variable
models were found to be signiﬁcant, thus only single‐variable
regressions are presented. In all tests, p< 0.05 was considered
signiﬁcant. Values of p< 0.10 are noted as trends.
Results
BAPN treatment reduces mouse growth and tibia
cortical size
Micewereweight‐matched into 4 treatment groups 2 days before
the start of treatment with group mean body weights of
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15.27 0.25 g (mean SEM) (Table 1). Although all mice gained
weight over the course of the 3‐week experiment, the highest
dose of BAPN signiﬁcantly reduced growth, resulting in signiﬁcant
differences in body weight by day 18 of the experiment (J‐T
p¼ 0.028). At death, mice at the highest dose weighed 7.5% less
than controls (J‐T p¼ 0.009, post hoc p< 0.05).
Tibia cortical cross‐sectional geometric measures were signi-
ﬁcantly reduced with BAPN treatment (Table 1). Tibia cross‐
sectional cortical area (Ct.Area) and TMC were signiﬁcantly
reduced with increasing BAPN dose (J‐T, p¼ 0.013 and p¼ 0.011,
respectively), as were the second moments of inertia about the
anterior‐posterior (IAP) and medial‐lateral axes (IML), indicating a
reduction of the cross section’s ability to resist bending in
both the A‐P and M‐L directions (J‐T, p¼ 0.007 and p¼ 0.038,
respectively). BAPN treatment had no signiﬁcant effects on
femur cortical geometry (Supplemental Table S1). Although
mean TMD for the tibia and femur were not different between
BAPN groups, tibial TMD became more variable with BAPN
treatment (Levene’s homogeneity of variance test, p< 0.05)
(Fig. 1).
BAPN treatment reduced pyridinoline cross‐linking and
cross‐link maturity ratios
BAPN signiﬁcantly reduced both species of pyridinoline cross‐
links compared with controls (Fig. 2A, ANOVA, HP: p¼ 0.025, LP:
p¼ 0.011, (HPþ LP): p¼ 0.019). Pyrroles were more abundant
than the pyridinolines for all doses of BAPN (Fig. 2A, two‐way
ANOVA with cross‐link measures treated as repeated measures,
p< 0.001). However, no signiﬁcant effect of BAPN dose on
pyrrole content was measured (Fig. 2A). No differences in the
immature cross‐links DHLNL and HLNL (Fig. 2B) or pentosidine
(Fig. 2C) with BAPN treatment were detected. Cross‐link maturity
ratios (Fig. 3) were signiﬁcantly reduced with BAPN treatment
when HP or (HPþ LP) was used as the measure of mature cross‐
links. We also compared the proportions between the hydroxyl-
ated and nonhydroxylated forms of the pyridinolines and
divalent cross‐links (HP:LP and DHLNL:HLNL, respectively) but
observed no signiﬁcant changes with BAPN treatment (data not
shown). There were no differences in the ratio of pyrroles to
pyridinolines either (data not shown).
Table 1. Mouse Body Weight and Tibia Cortical Geometry Measures
BAPN dose (mg/kg body weight)
p Value0 150 350 500
Body weight
Day‐2 (g) 15.4 (14.7–15.9) 15.4 (14.6–16.0) 15.3 (14.3–16.0) 15.2 (14.6–16.0)
Day 18 (g) 20.4a (20.0–21.5) 20.8a (20.3–21.8) 20.6a (19.6–21.4) 19.1b (18.5–20.3) 0.028
Day 22 (g) 21.5a (20.1–22.2) 21.1a (19.9–22.1) 20.5 (19.4–21.2) 19.9b (18.9–20.9) 0.009
Tibia
Length (mm) 16.70 (16.56–16.79) 16.81 (16.58–16.88) 16.76 (16.45–16.90) 16.61 (16.42–16.81)
TMC (mg HA) 49.0a (47.7–52.1) 46.7a (44.9–51.1) 47.6 (45.5–49.7) 45.1b (44.0–47.4) 0.011
Ct.Area (mm2) 0.543a (0.534–0.569) 0.532a (0.495–0.579) 0.529 (0.503–0.550) 0.503b (0.489–0.540) 0.013
Ct.Th (mm) 0.163 (0.160–0.175) 0.161 (0.154–0.178) 0.163 (0.154–0.172) 0.157 (0.150–0.164) 0.052
IAP (mm
4) 0.051a (0.046–0.054) 0.049a (0.048–0.053) 0.046 (0.045–0.052) 0.044b (0.040–0.049) 0.007
IML (mm
4) 0.070a (0.065–0.081) 0.069 (0.059–0.078) 0.066 (0.057–0.077) 0.062b (0.051–0.067) 0.038
AP.W (mm) 1.271 (1.219–1.351) 1.274 (1.193–1.343) 1.244 (1.194–1.317) 1.215 (1.154–1.267) 0.072
ML.W (mm) 1.137 (1.104–1.157) 1.143 (1.119–1.157) 1.127 (1.104–1.140) 1.121 (1.084–1.147) 0.099
AP/ML ratio 1.108 (1.063–1.174) 1.113 (1.075–1.139) 1.115 (1.049–1.158) 1.095 (1.047–1.150)
Data presented as median (interquartile range).
TMC¼ tissue mineral content; HA¼hydroxyapatite; Ct.Area¼ cortical area; Ct.Th¼ cortical thickness; IAP¼moment of inertia about anterior‐posterior
axis; IML¼moment of inertia about medial‐lateral axis; AP.W¼ anterior‐posterior width; ML.W¼medial‐lateral width.
Effect of BAPN tested using Jonckheere‐Terpstra nonparametric test; post hoc differences indicated as bsigniﬁcantly different from a(p< 0.05).
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Fig. 1. Group distributions of TMD measured at the standard site are
presented in a statistical boxplot. Black horizontal bars indicate group
median, box ends indicate the 25th and 75th percentiles of the data, box
height is the interquartile range (IQR) of the data, and whisker lines
indicate themaximum andminimum values that are not outliers. Outliers
are shown as individual dots. TMD was not signiﬁcantly altered by dose
for either bone, but tibia TMD variability was signiﬁcantly increased by
BAPN treatment, illustrated by the increased IQR in BAPN‐treated groups
(Levene’s test for homogeneity of variance, p¼ 0.026).
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Bone fracture toughness is reduced with intermediate
doses of LOX inhibitor
Maximum load fracture toughness (KC.Max) reﬂects the energy
required for crack initiation and was signiﬁcantly affected by
BAPN treatment (Fig. 4, ANOVA p¼ 0.010). The 150mg/kg
(p¼ 0.040) and 350mg/kg (p¼ 0.019) doses led to reductions in
KC.Max of 15.5% and 18.2%, respectively. No difference was found
between the 500mg/kg dose and controls. Although the data
suggest a reduction in instability toughness (KC.Inst) at the
350mg/kg dose, there was not a signiﬁcant effect of BAPN dose
(ANOVA p¼ 0.408).
Bone strength, but not stiffness, is reduced at both the
structural and tissue levels with intermediate doses of
BAPN
Signiﬁcant reductions in structural strength occurred with BAPN
treatment (Fig. 5B). Increasing BAPN dose reduced yield (J‐T,
p¼ 0.054) and ultimate (J‐T, p¼ 0.02) strength (Fig. 5B).
Estimated material properties (Fig. 5D–F) were also impacted
by BAPN treatment, with signiﬁcant reductions in yield (ANOVA,
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fracture toughness were found at the intermediate (350mg/kg) BAPN
dose. p< 0.05.
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p¼ 0.038) and ultimate (ANOVA, p¼ 0.044) stress (Fig. 5E). The
greatest reductions were not at the highest dose but at the
intermediate 350mg/kg dose. An effect of BAPN on pre‐yield
toughness was marginally signiﬁcant (Fig. 5F, p¼ 0.086). The
majority of bones, including controls, sustained signiﬁcant
deformation (>1mm), necessitating test termination without a
deﬁned fracture point and precluding the collection of failure
load, failure deformation, and work to fracture data.
Pyridinoline cross‐links and cross‐link maturity are
regressors of bone strength and toughness
Themature/immature cross‐link ratio of HP/(DHLNLþHLNL) was
the strongest regressor of instability fracture toughness
(r2¼ 0.208, p< 0.05), whereas quantities of mature pyridinoline
cross‐links were signiﬁcant positive regressors of tissue strength
(LP r2¼ 0.159, p¼ 0.014; HP r2¼ 0.112, p< 0.05) (Table 2).
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Fig. 5. Whole‐bone (A–C) and tissue level (D–F) mechanical properties measured by four‐point bending of the tibia. Ultimate strength (B) was signiﬁcantly
reduced by BAPNwith signiﬁcant decreases detected for the 350 and 500mg/kg groups. Yield strength (B) showed the same trend. Yield and ultimate stress
(E) were signiﬁcantly reduced by BAPN. Speciﬁc group differences were found between the 0 and 350mg/kg doses. A marginally signiﬁcant effect of BAPN
on pre‐yield toughness (F) was observed. No signiﬁcant differences were detected for stiffness (A), pre‐yield work (C), or modulus (D). p< 0.05, †p< 0.10.
Table 2. Linear Regression of Mechanics and Cross‐Linking
R2 linear regression KC.Max KC.Inst Yield stress Ultimate stress Pre‐yield toughness
Pyrrole (fit using sq.) 0.068
HP 0.073 0.073 0.089^ 0.112 0.069
LP 0.152 0.159 0.118
HLNL 0.095(–)
PEN (fit using log) 0.147 0.157^
HPþ LP 0.057 0.065 0.106 0.128 0.082
HPþ LPþ Pyrrole 0.12
(HPþ LP)/(DHLNLþHLNL) 0.120 0.196^ 0.067
HP/(DHLNLþHLNL) 0.126 0.208 0.052
HP/DHLNL 0.172^
(HPþ LP)/DHLNL 0.162^
LP/HLNL 0.145 0.059 0.055 0.050
Pyrroles/pyridinolines 0.081(–) 0.133(–)
R2< 0.05 not shown for clarity. TMD, DHLNL, (DHLNLþHLNL), and modulus had R2< 0.05 for all metrics and are not shown.
p< 0.05, ^p< 0.10; (–) indicates negative relationship. Pre‐yield toughness ﬁt using inverse transform (signs corrected to reﬂect raw data relationship).
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Additional ratios reﬂecting cross‐link maturity were marginally
signiﬁcant regressors of KC.Inst. Pyridinoline cross‐links had
signiﬁcant explanatory power both individually (HP and LP)
and summed (HPþ LP) for bone strength. Nomodels found TMD
to be a signiﬁcant factor in explaining mechanical properties.
Raman spectroscopy detects localized effects of BAPN
treatment on new tissue as increases in the 1660/1683
ratio
Calcein images were referenced to classify each site of Raman
collection as new or preexisting tissue (Supplemental Fig. S1).
The cross‐linking ratio (Fig. 6C) was signiﬁcantly increased in new
BAPN‐treated bone compared with newly formed control bone.
Within new (treated) tissue, BAPN treatment did not have
signiﬁcant effects on mineral measures (phosphate content or
carbonate substitution) (Fig. 6A, B). Signiﬁcant differences
between new (treated) and old (preexisting normal) tissues
were identiﬁed for all Raman measures in all groups, with older
tissue having signiﬁcantly greater mineral/matrix, carbonate/
phosphate, and matrix maturity ratio measures than newly
formed tissues (Fig. 6A–C). Notably, when data were averaged
based on cortical location alone (ignoring calcein labels and
averaging within mid‐cortical and endocortical sites), BAPN’s
impact on cross‐link maturity was masked (Table 3). As was the
case for bone, cell matrix 1660/1683 ratio was signiﬁcantly
increased by BAPN treatment (Fig. 6C).
Discussion
The toughness of bone stems largely from the properties of its
polymeric organic matrix. Covalent collagen cross‐links are
responsible for stabilizing this ﬁbrillar network. It has long been
understood that the inhibition of enzymatic cross‐linking results
in a reduction in bone strength,(1,15,43) but the degree to which
cross‐links are capable of directly contributing to bone
mechanics, particularly fracture toughness, is unknown. To our
knowledge, this is the ﬁrst report to measure the impact of
collagen cross‐linking on bone fracture toughness. We found a
signiﬁcant reduction in directly measured bone fracture
toughness as a result of cross‐link inhibition (Fig. 4). Reduced
fracture toughness was accompanied by a signiﬁcant reduction
in tibia whole‐bone strength (ultimate load) and estimated
material level properties (yield stress and ultimate stress) for the
intermediate BAPN dose (Fig. 5).
Ratios reﬂecting relative cross‐link maturity were signiﬁcant
explanatory variables of fracture toughness, whereas quantities
of mature pyridinoline cross‐links were signiﬁcant regressors of
tissue strength (Table 2). There was a stronger association
between pyridinoline content and strength and toughness than
pyrrole content (Table 2). The pyrrole colorimetric assay is a
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Fig. 6. Raman spectroscopy measures. New tissues had signiﬁcantly lower mineral:matrix (A), carbonate:phosphate (B), and matrix maturity (1660/1683)
ratio (C) compared with older, preexisting tissues. Within new treated tissue, BAPN did not have signiﬁcant effects on mineral measures but signiﬁcantly
increased the matrix maturity ratio (C). MC3T3‐E1 cell culture matrix cultured with BAPN had increased 1660/1683 compared with control cultures (C).
p< 0.05.
Table 3. Comparison of Site‐Speciﬁc Analyses of Raman Bone
Measurements
Factor
Repeated
measures 2‐way ANOVA
ANOVA
(within new tissue)
Age (calcein label) BAPN BAPN
1660/1683 p< 0.001 p¼ 0.002 p¼ 0.001
1660/870 p¼ 0.001 p¼ 0.396 p¼ 0.266
1683/870 p¼ 0.004 p¼ 0.587 p¼ 0.529
958/1002 p< 0.0001 p¼ 0.415 p¼ 0.546
1070/958 p< 0.0001 p¼ 0.299 p¼ 0.610
Endo versus
mid‐cortical
1660/1683 p< 0.001 p¼ 0.392
1660/870 p¼ 0.005 p¼ 0.971
1683/870 p¼ 0.040 p¼ 0.959
958/1002 p¼ 0.091 p¼ 0.895
1070/958 p¼ 0.760 p¼ 0.108
Raman spectra were averaged for new and preexisting tissue within
each bone ﬁrst based on calcein labeling and then using a broad
deﬁnition of mid‐cortical (old) versus endocortical (new) bone.
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noisier measure than the HPLC quantiﬁcation of pyridinoline,
and it is possible this variability reduced our ability to detect
signiﬁcance in pyrrole differences and regressions. The plentiful
immature cross‐links failed to correlate with bone strength,
whereas reductions in the smaller fraction of mature cross‐links
resulted in measurable losses of tissue strength and fracture
toughness. These correlations strengthen the argument that
trivalent cross‐links play a greater role than the divalent cross‐
links in stabilizing the organic matrix of bone.
BAPN treatment signiﬁcantly reduced maximum load tough-
ness but not instability toughness (Fig. 4). This may be explained
by the greater variance in the measurement of KC.Inst than KC.Max,
reducing its power to statistically detect differences between
groups. Yet, KC.Inst regressed more strongly than KC.Max with
cross‐link proﬁle and with measures of bone strength deter-
mined from whole‐bone bending (Table 2). KC.Inst includes
contributions of both crack initiation and stable crack growth
and is considered a better single‐point fracture toughness
estimate than KC.Max.
(34) The signiﬁcant association between
cross‐link maturity and KC.Inst but not KC.Max suggests the
possibility that having more mature cross‐links relative to
immature is supportive of stable crack growth.
We originally hypothesized that a decrease in collagen cross‐
linking with concomitant decreases in mechanical properties
would occur as BAPN dose increased. However, mechanical
properties were reduced most signiﬁcantly at the intermediate
(350mg/kg) rather than highest (500mg/kg) BAPN dose (Figs. 4
and 5). Others have observed similar discontinuities in BAPN
dose effects in vascular tissues.(44) BAPN does not alter existing
cross‐links. Thus, at the end of the experiment, each mouse is a
hybrid of normal and cross‐link–deﬁcient tissues in proportions
determined by the rates of tissue apposition and removal. The
dose‐dependent reduction in weight gain and bone cortical area
with BAPN treatment (Table 1) support there being less new
(BAPN‐treated) cortical tissue formed at the highest BAPN dose
compared with the other groups. It is also possible that BAPN
increased osteoclast number or activity, contributing to reduced
bone size.(45) Regardless of the cellular mechanism, the lack of
effect on strength and toughness at the highest BAPN dose could
be explained by a reduction or change in distribution of the
cross‐link–deﬁcient tissue. The potential for a volume averaging
of preexisting and experimentally treated tissue to inﬂuence
experimental measurements is an often overlooked confound-
ing factor with broad implications in skeletal research.
The HPLC quantiﬁcation of cross‐links from bulk tissue, while
allowing for speciﬁc measurement of the full cross‐link proﬁle,
reﬂects a volume averaging of preexisting and normal tissue. To
address this issue, Raman spectroscopy was used to explore the
spatial effect of BAPN treatment on matrix cross‐linking and
composition. Raman revealed a localized increase in the matrix
maturity ratio (1660/1683 cm1) with LOX inhibition, as well as a
strong effect of relative tissue age on both mineral and matrix
maturity measures (Fig. 6). It is worth noting that the interpretation
of the 1660/1683 cm1 ratio is still controversial.(27,46) Although
the ratio was ﬁrst reported to correspond to the nonreducible/
reducible cross‐link ratio using FTIR(47) and has since been widely
employed in both the FTIR and Raman spectroscopy literature, it is
not a direct measurement of cross‐link content. Two component
bands of Amide I near 1660 and 1683 cm1 represent different
secondary structures of collagen. Thus, the ratio can be changed by
factors other than aging, such as mechanical damage,(48) ionizing
radiation,(41,49) exercise,(50) and dehydrationof bone,(51) all of which
cause changes in collagen secondary structure.
Because the 1660/1683 cm1 ratio is sensitive to tissue age,
this sensitivity can overshadow the effects from BAPN treatment
if areas of new tissue formation are assumed from cortical
location alone. This is illustrated by a lack of signiﬁcance when
tissue measures were averaged by cortical location rather than
by calcein labeling (Table 3). Because of the magnitude of the
increase in the ratio we observed with increasing tissue age
(older preexisting tissue compared with new control tissue,
Fig. 6C), it is possible the increase in 1660/1683 cm1 observed in
newly formed BAPN‐treated tissuemay bemasked at time points
later than we examined, after tissue maturation.
The Raman1660/1683 cm1 ratiowas increased both by BAPN
treatment and with relative tissue age, yet direct quantiﬁcation by
HPLC found signiﬁcant reductions in mature cross‐links and
relative cross‐link maturity. An increase in the spectroscopic matrix
maturity ratio was similarly observed by FTIR after BAPN ingestion
in rats, but the increase was attributed to disproportionate
decreases of HPLC‐measured nonreducible and reducible cross‐
link concentrations in BAPN‐treated specimens compared with
controls.(27) Combined, these results demonstrate that an increase
in the 1660/1683 cm1 ratio does not directly indicate an increase
in the number of mature cross‐links, highlighting the nonquanti-
tative nature of this measure and the necessity for care in its
interpretation. Although the ratio is not an absolute quantiﬁcation
of cross‐link maturity, the present results highlight an ability of
Raman spectroscopy to detect localized matrix differences
attributable to cross‐linking deﬁciencies, if carefully controlling
for treatment history and relative age of the tissue.
Ourmodel of BAPN treatment resulted in a signiﬁcant reduction
in mature enzymatic cross‐links, but with a greater reduction of LP
than HP (Fig. 2), in agreement with others’ results.(27) However, we
did not observe any change in immature cross‐links with BAPN
treatment, resulting in a reduced ratio of mature to immature
cross‐links (Fig. 3). The reduced ratio of mature to immature cross‐
links from BAPN treatment does not appear to reﬂect a general
perturbation of tissue maturation. Raman measurements showed
mineralization in the newly formed BAPN‐treated tissue to be
equivalent to controls, and BAPN actually increased the 1660/
1683 cm1 ratio in new bone (Fig. 6), an observation typically
associated with an increase in matrix maturity.
Thematuration of the divalent cross‐links to the trivalent cross‐
link forms is dependent on the presence of another (hydroxy)
lysyl‐aldehyde, created by LOX activity. It is interesting to consider
that we may have developed a mild lathyrism model capable of
just enough inhibition to limit the formation of trivalent cross‐
links, while allowing normal levels of immature cross‐linking to
develop. It is also possible that metabolism and clearance of the
inhibitor permits LOX activity, and thereby immature cross‐
linking, to recover between the daily BAPN injections.
Our results show correlations between cross‐link proﬁle and
mechanical properties, but alterations in cross‐link proﬁle may
alter the response of osteoblasts and osteoclasts, initiating a cell‐
mediated cascade of changes to tissue quality.(42,45,52,53) The
inhibition of cross‐linking may affect bone composition and
mechanical properties indirectly through these changes in
addition to a direct mechanical contribution to matrix stability.
However, we did not detect any matrix alterations outside of
cross‐link proﬁle to explain the mechanical effects of BAPN
treatment (Fig. 6). The effects of BAPN treatment on bone
mineralization aremixed.(27,28,30,54) TMD is typically expected to be
a primary determinant of bone stiffness, but mean TMD, like
stiffness, was not signiﬁcantly changedwith cross‐link inhibition in
this model and was not a signiﬁcant correlate of any mechanical
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property. Cortical TMD at the tibia standard site wasmore variable
with BAPN treatment (Fig. 1), but the BAPN reduction of bone size
and the differences in phosphate/matrix and carbonate/phos-
phate observed with tissue age, but not BAPN treatment, suggest
this increased TMD variability is attributable to variability in the
volume fractions of new and old tissue rather than effects of BAPN
on new tissue mineralization. It is possible that BAPN treatment
caused unobserved changes to mineral composition or tissue
structure that contributed to the decreases in material strength
and fracture toughness.
Considering the possibility that BAPN treatmentmight promote
differences in collagen ﬁbril deposition or organization to
indirectly alter mechanical properties, we observed the embed-
ded tibia cross sections with a cross‐polarized light microscope to
assess collagen alignment via its natural birefringence using the
light intensity (IBrightﬁeld/IDarkﬁeld) ratio.
(55) We observed collagen
alignment differences between anatomical locations as others
have observed,(56) but therewas no indication of BAPN having any
impact on collagen alignmentwithin areas of newbone formation
(data not shown). Others have observed differences in ﬁbril size
distribution with BAPN.(57,58) Perhaps there is a dosage effect of
BAPN on ﬁbril morphology, which is responsible for the dose‐
speciﬁc mechanical results observed in our study.
The relationships between cross‐linking and mechanical
properties were observed in young mice, demonstrating the
sufﬁciency of cross‐link changes to affect bone quality in this
population at least. Because only youngmice were included in this
experiment, further study exploring the interaction of cross‐linking
perturbations with aging and disease‐associated changes in bone
quality, such as increased mineralization and damage accumula-
tion, is needed to extend these ﬁndings to an older population.
However, we expect that collagen cross‐links similarly contribute
to the fracture toughness of adult tissues, as the inclusion of
speciﬁc mature enzymatic collagen cross‐link measures signiﬁ-
cantly improved regression models predicting strength, stiffness,
and ultimate strain in human adult cancellous bone.(59)
Our study reveals that spatially localized effects of short‐term
BAPN cross‐link inhibition can signiﬁcantly affect whole‐bone
collagen cross‐link proﬁle and reduce both fracture toughness
and bone strength. The speciﬁc reduction of pyridinoline cross‐
links and the associated decrease in pyridinoline to immature
cross‐link ratios were associated with a reduction in bone
strength and fracture toughness, respectively. Thus, cross‐link
proﬁle perturbations associated with bone disease may provide
insight into bone mechanical quality and fracture risk.
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